靶向STK17B激酶激活铁死亡并抑制多发性骨髓瘤耐药
该研究鉴定STK17B激酶为多发性骨髓瘤中铁死亡的关键抑制因子,其高表达与患者总生存期差相关,且在复发患者中显著高于新诊断患者。抑制STK17B可增加不稳定铁池、增强脂质过氧化并使细胞对常规抗骨髓瘤治疗敏感,口服STK17B抑制剂在移植瘤小鼠模型中诱导铁死亡并显著减少肿瘤生长。机制上STK17B磷酸化IREB2(S157)和HSPB1(S15),并间接维持STAT3活化磷酸化,形成可靶向的STK17B-pIREB2S157/pHSPB1S15信号轴。
要点
- STK17B高表达与MM患者总生存期差相关,复发患者表达显著高于新诊断患者。
- 抑制STK17B增加不稳定铁池、增强脂质过氧化并增敏常规抗MM治疗。
- 口服STK17B抑制剂在MM移植瘤小鼠模型中诱导铁死亡并显著减少肿瘤生长。
核心结论
- 研究揭示临床相关且可靶向的STK17B-pIREB2S157/pHSPB1S15信号轴抑制铁死亡并参与MM耐药。
研究设计与样本
- 研究采用邻近标记 assay 结合磷酸化蛋白质组学分析,并在MM细胞和MM移植瘤小鼠模型中进行功能验证。
主要发现
- STK17B表达水平升高与MM患者总生存期差相关,且复发MM病例中STK17B表达显著高于新诊断病例。
- 抑制MM细胞中STK17B可增加不稳定铁池、增强脂质过氧化并使细胞对常规抗MM治疗敏感。
- 口服可及的内部生成STK17B抑制剂在MM移植瘤小鼠模型中诱导铁死亡并显著减少肿瘤生长。
- 邻近标记 assay 结合磷酸化蛋白质组学分析鉴定IREB2和HSPB1为STK17B的直接靶点。
- STK17B磷酸化IREB2的S157和HSPB1的S15,调节IREB2与HSPB1下游效应物(促铁死亡的转铁蛋白受体和抗铁死亡的重链铁蛋白)之间的平衡。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The progression of multiple myeloma (MM), an incurable malignancy of plasma cells, is often associated with the suppression of ferroptosis, a type of cell death driven by iron-dependent lipid peroxidation. The mechanisms underlying this suppression remain largely unknown. Here, we identified serine/threonine kinase 17b (STK17B) kinase as a critical suppressor of ferroptosis in MM. Elevated levels of STK17B are associated with poor overall survival in patients with MM, and STK17B expression is significantly higher in relapsed vs newly diagnosed MM cases. We found that inhibiting STK17B in MM cells increased the labile iron pool, enhanced lipid peroxidation, and sensitized cells to conventional anti-MM therapies. Notably, an orally available, in-house-generated STK17B inhibitor induced ferroptosis and significantly reduced tumor growth in MM xenograft mouse models. Mechanistically, proximity labeling assay combined with the phospho-proteomic analysis identified 2 major regulators of iron uptake and transport as direct targets of STK17B: iron-responsive element binding protein 2 (IREB2), and heat shock protein family B member 1 (HSPB1). We demonstrated that STK17B phosphorylates critical regulatory sites on IREB2 (S157) and HSPB1 (S15), thereby modulating the balance between IREB2 and HSPB1 downstream effectors, proferroptotic transferrin receptor, and antiferroptotic ferritin heavy chain proteins. Furthermore, we demonstrated that STK17B indirectly maintains activating phosphorylation of STAT3, a ferroptosis suppressor and a major driver of MM pathobiology. Our findings uncovered a clinically relevant and targetable STK17B-pIREB2S157/pHSPB1S15 signaling axis that suppresses ferroptosis and contributes to drug resistance in MM.
引用
- Yan Z, Han Z, Wang Y, et al. Targeting STK17B kinase activates ferroptosis and suppresses drug resistance in multiple myeloma. Blood. 2026. PMID: 40953235. doi:10.1182/blood.2025029950
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。